Altimmune to Announce Second Quarter 2020 Financial Results on August 12
Conference Call Details |
|
Date: | |
Time: | |
Domestic: | 877-423-9813 |
International: | 201-689-8573 |
Conference ID: | 13706947 |
Webcast: | http://public.viavid.com/index.php?id=140748 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor Contacts: | |
Chief Financial Officer | |
Phone: 240-654-1450 | 617-430-7577 |
wbrown@altimmune.com | arr@lifesciadvisors.com |
Media Contacts: | |
Phone: 212-687-8080 | |
altimmune-svc@sardverb.com |
Source: Altimmune, Inc.